Primary central nervous system lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b/> In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the central nervous system.
|
28864640 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b/> In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the central nervous system.
|
28864640 |
2017 |
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
|
30975981 |
2019 |
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of ibrutinib, a first-in-class oral inhibitor of Bruton tyrosine kinase (BTK), for the treatment of relapsed/refractory (R/R) and/or TP53 mutated patients with CLL.
|
31732977 |
2019 |
Chronic lymphocytic leukaemia refractory
|
0.010 |
Biomarker
|
disease |
BEFREE |
At the present time, GS-1101, which reversibly inhibits PI3Kδ, and ibrutinib (PCI-32765), an irreversible inhibitor of Bruton tyrosine kinase, have generated the most promising early results in clinical trials including predominately refractory CLL where durable disease control has been observed.
|
22715122 |
2012 |
Lymphoproliferative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Atrial fibrillation is a side effect of ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase used for treatment of B-cell lymphoproliferative disorders.
|
29475534 |
2018 |
Diffuse Large B-Cell Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Deletions of CDKN2A/B (28%) and IBTK (23%) were frequent events in relapsed DLBCLs.
|
27276707 |
2016 |
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton's tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX).
|
31371481 |
2019 |
Nephroblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
For example, the IBtK protein and the SH2 domain-containing protein were present in siRNA(WT1) conditions, while the platelet-derived growth factor receptor α (PDGFRA) and Rho guanine nucleotide exchange factor 1 (Rho-GEF 1) were expressed in siRNA(neg).
|
24503937 |
2014 |
Nonalcoholic Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Function of inhibitor of Bruton's tyrosine kinase isoform α (IBTKα) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response.
|
28710282 |
2017 |
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further, the expression of IBTK gene progressively increases from indolent to aggressive stage of chronic lymphocytic leukemia and decreases in disease remission after therapy.
|
30975981 |
2019 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Here, we report that loss of the murine Ibtk gene raises survival and delays tumor onset in Eμ-myc transgenic mice, a preclinical model of Myc-driven lymphoma.
|
30975981 |
2019 |
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we report that loss of the murine Ibtk gene raises survival and delays tumor onset in Eμ-myc transgenic mice, a preclinical model of Myc-driven lymphoma.
|
30975981 |
2019 |
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report that loss of the murine Ibtk gene raises survival and delays tumor onset in Eμ-myc transgenic mice, a preclinical model of Myc-driven lymphoma.
|
30975981 |
2019 |
Childhood Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report that loss of the murine Ibtk gene raises survival and delays tumor onset in Eμ-myc transgenic mice, a preclinical model of Myc-driven lymphoma.
|
30975981 |
2019 |
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
However, the role of IBTK in tumorigenesis has not been elucidated.
|
30975981 |
2019 |
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib (also referred to as PCI-32765), an inhibitor of Bruton's tyrosine kinase, while its effects on multiple myeloma have not been well described.
|
29320977 |
2018 |
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Ibrutinib (IBT), the first-in-class inhibitor of Bruton's tyrosine kinase (BTK), has demonstrated clinical activity against various B-cell malignancies.
|
30760494 |
2019 |
B-Cell Lymphomas
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Ibrutinib (Imbruvica<sup>®</sup>) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kinase expressed by various haematopoietic cells, B-cell lymphomas and leukaemias.
|
28105602 |
2017 |
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Ibrutinib (Imbruvica<sup>®</sup>) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kinase expressed by various haematopoietic cells, B-cell lymphomas and leukaemias.
|
28105602 |
2017 |
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).
|
24869598 |
2014 |
Lymphoproliferative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders.
|
28182323 |
2017 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of B-cell malignancies.
|
30090839 |
2018 |
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase, which is one of the key drugs used for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
|
30421802 |
2019 |
Mantle cell lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase, which is one of the key drugs used for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
|
30421802 |
2019 |